1 Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
2 Department of Pharmaceutical and Health Economics, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles.
3 Yale School of Medicine, New Haven, Connecticut.
This cross-sectional study examines the pre–Inflation Reduction Act out-of-pocket burden on Medicare patients taking dapagliflozin, empagliflozin, and sacubitril/valsartan.